Biotech Values

[DewDiligence]

NVS’ Entresto might increase risk of AMD and AD, say journal authors:

http://www.medpagetoday.com/Cardiology/CardioBrief/55107?xid=nl_mpt_DHE_2015-12-10&eun=g655567d0r

The concerns, raised in a Journal of the American Medical Association viewpoint article…focus on the possibility that a key mechanism of the drug, neprilysin inhibition, may have troubling repercussions in the central nervous system and the eye. Entresto is a combination of the novel neprilysin inhibitor sacubitril and the older, well-established angiotensin receptor antagonist valsartan [a/k/a Diovan].

NVS expects Entresto to have peak worldwide sales of at least $5B (some analysts are even higher), so these safety concerns, although just conjecture at this point, are no small matter.